Fred Alger Management 13F: Adds $69M to JNJ Stake

Fred Alger Management has increased its stake in Johnson & Johnson (NYSE:JNJ) by a notable 416%, according to its latest Form 13F filing with the SEC. The fund added 269,777 shares during the reporting period, bringing its total holdings to 334,592 shares, valued at approximately $80.6 million.

What Changed in Fred Alger Management's Johnson & Johnson Position

Fred Alger Management boosted its investment in Johnson & Johnson significantly, increasing its holdings by 416%. The fund went from owning 64,815 shares to 334,592 shares, adding 269,777 shares in the process. This substantial increase reflects a strong vote of confidence in the healthcare giant.

Other Institutional Activity in Johnson & Johnson

Several other institutional investors also made moves in Johnson & Johnson. BlackRock, Inc. increased its holdings by 4.6 million shares, ending with 213.4 million shares valued at about $52.2 billion, a 2.2% increase. Vanguard Capital Management LLC opened a new position with 156.6 million shares worth approximately $38.3 billion. State Street Corp trimmed its stake by 393,555 shares to 133.5 million shares, a slight 0.3% decrease in holdings. JPMorgan Chase & Co expanded its position by 4.5 million shares, now holding 63.1 million shares valued at $15.3 billion, marking a 7.7% increase.

Johnson & Johnson Stock Holds Steady

Shares of Johnson & Johnson traded around $241 on Thursday. The company boasts a market capitalization of about $556.8 billion, with a P/E ratio of 26.8 and a forward P/E of 18.2. Its stock has a 52-week low of $149.74 and a high of $251.71. The 50-day moving average stands at $230.37, while the 200-day moving average is $215.73. Johnson & Johnson maintains a current ratio of 1.03 and a quick ratio of 0.69, with a debt-to-equity ratio of 67.73.

Recent Earnings

Johnson & Johnson reported revenues of $96.36 billion, reflecting a growth rate of 9.9%. The company's net margin was 21.8%, and it achieved a return on equity of 26.4%. Earnings per share stood at $8.63. The next earnings report is scheduled for July 15, 2026.

Dividend

Johnson & Johnson offers an annual dividend rate of $5.36, yielding 2.35%. The company's dividend payout ratio is 60.25%.

Insider Buying and Selling at Johnson & Johnson

On June 11, 2026, Kathryn Wengel, EVP and Chief TO and Risk Officer, sold 10,000 shares at an average price of $241.15. On the same day, she also bought 10,000 shares at $115.67. Other insider transactions include Marillyn Hewson purchasing 215 shares, Eugene Woods buying 161 shares, and Daniel Pinto acquiring 134 shares, all at $232.79 on June 9, 2026.

Analysts Set New Price Targets

On May 13, 2026, Leerink Partners upgraded Johnson & Johnson to a 'buy' rating with a price target of $265. Barclays maintained its 'hold' rating with a $255 target on April 15, 2026. Wells Fargo also maintained a 'buy' rating with a $263 target. The consensus among 23 analysts is a 'buy', with a mean price target of $252.87.

About Johnson & Johnson

Johnson & Johnson is a global leader in healthcare, focusing on research, development, and manufacturing of innovative products. Based in New Brunswick, New Jersey, the company operates through its Innovative Medicine and MedTech segments. It provides a range of products across therapeutic areas like oncology, immunology, and cardiovascular health. The company, led by CEO Joaquin Duato, employs about 138,200 people worldwide.

Bottom Line

Fred Alger Management's substantial increase in its Johnson & Johnson holdings reflects a strong belief in the company's prospects. With a solid market position and promising financials, Johnson & Johnson remains a closely watched stock. As always, note that 13F filings are historical and may not represent current positions.